Clinical Trial Update: Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine hydrochloride, cisplatin, and nab-paclitaxel for advanced or metastatic biliary cancers has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma
• Stage Iiia Gallbladder Cancer
• Stage Iiib Gallbladder Cancer
• Stage Iva Gallbladder Cancer
• Stage Iva Intrahepatic Cholangiocarcinoma
• Stage Ivb Gallbladder Cancer
• Stage Ivb Intrahepatic Cholangiocarcinoma
• Unresectable Extrahepatic Bile Duct Carcinoma
• Unresectable Gallbladder Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2022-02-02